People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Indalo Therapeutics, Inc. | — | Pharmaceuticals | Series A | $9.7M | $278.7M | 2017 |
Ben H. Auspitz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ben H. Auspitz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Charles Bolten | 1 | 10 |
| Robert W. Karr | 1 | 4 |
| David W. Griggs | 1 | 1 |
| Rajesh P. Devraj | 1 | 1 |
| Thomas P. Cirrito | 1 | 1 |
| Michael W. Yeadon | 1 | 1 |
| Michael A. Yeadon | 1 | 1 |
| Bradford H. Williamson | 1 | 1 |
| Scott H. Seiwert | 1 | 1 |
| Peter H. Barrett | 1 | 1 |
| Rajesh H. Devraj | 1 | 1 |
| George H. Capps, II | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.